Biological Activities of p53 Mutants in Burkitt's Lymphoma Cells

References

1. Baker S. J., Markowitz S., Fearon E. R., Willson J. K. V., Vogelstein B. 1990; Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249:912–915
   [Google Scholar]
2. Banks L., Matlashewski G., Crawford L. 1986; Isolation of human p53 specific monoclonal antibodies and their use in the studies of human p53 expression. European Journal of Biochemistry 159:529–534
   [Google Scholar]
3. Ciechanover A., Digiuseppe J. A., Bercovich B., Orian A., Richter J. D., Schwartz A. L., Brodeur G. M. 1991; Degradation of nuclear oncoproteins by the ubiquitin system in vitro. Proceedings of the National Academy of Sciences, U.S.A. 88:139–143
   [Google Scholar]
4. Crook T., Vousden K. H. 1992; Properties of p53 mutations detected in primary and secondary cervical cancers suggests mechanisms of metastasis and involvement of environmental carcinogens. EMBO Journal 11:3935–3940
   [Google Scholar]
5. Crook T., Fisher C., Vousden K. H. 1991a; Modulation of immortalizing properties of human papillomavirus type 16 E7 by p53 expression. Journal of Virology 65:505–510
   [Google Scholar]
6. Crook T., Tidy J. A., Vousden K. H. 1991b; Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell 67:547–556
   [Google Scholar]
7. Diller L., Kassel J., Nelson C. E., Gryka M. A., Litwak G., Gebhardt M., Bressac B., Ozturk M., Baker S. J., Vogelstein B., Friend S. H. 1990; p53 functions as a cell cycle control protein in osteosarcomas. Molecular and Cellular Biology 10:5772–5781
   [Google Scholar]
8. Farrell P. J., Allan G. J., Shanahan F., Vousden K. H., Crook T. 1991; p53 is frequently mutated in Burkitt’s lymphoma cell lines. EMBO Journal 10:2879–2887
   [Google Scholar]
9. Fields S., Jang S. K. 1990; Presence of a potent transcription activating sequence in the p53 protein. Science 249:1046–1049
   [Google Scholar]
10. Gaidano G., Ballerini P., Gong J. Z., Inchirami G., Neri A., Newcomb E. W., Magrath I. T., Knowles D. M., Dalla-Favera R. 1991; p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proceedings of the National Academv of Sciences, U.S.A. 88:5413–5417
    [Google Scholar]
11. Gannon J. V., Greaves R., Iggo R., Lane D. P. 1990; Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO Journal 9:1595–1602
    [Google Scholar]
12. Ginsberg D., Mechta F., Yaniv M., Oren M. 1991; Wild-type p53 can down-modulate the activity of various promoters. Proceedings of the National Academy of Sciences, U.S.A. 88:9979–9983
    [Google Scholar]
13. Hinds P. W., Finlay C. A., Quartin R. S., Baker S. J., Fearon E. R., Vogelstein B., Levine A. J. 1992; Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the ‘hot spot’ mutant phenotypes. Cell Growth and Differentiation I:571–580
    [Google Scholar]
14. Hirt B. 1967; Selective extraction of polyoma DNA from infected mouse cell cultures. Journal of Molecular Biology 26:365–369
    [Google Scholar]
15. Hollstein M., Sidransky D., Vogelstein B., Harris C. C. 1991; p53 mutations in human cancers. Science 253:49–53
    [Google Scholar]
16. Huibregtse J. M., Scheffner M., Howley P. M. 1991; A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO Journal 10:4129–4135
    [Google Scholar]
17. Lane D. P. 1992; p53, guardian of the genome. Nature, London 358:15–16
    [Google Scholar]
18. Lane D. P., Benchimol S. 1990p53 oncogene or anti-oncogene?. Genes and Development 4:1–8
    [Google Scholar]
19. Lane D. P., Crawford L. V. 1979; T antigen is bound to a host protein in SV40-transformed cells. Nature, London 278:261–263
    [Google Scholar]
20. Lau R., Packham G., Farrell P. J. 1992; Differential splicing of Epstein-Barr virus immediate early RNA. Journal of Virology 66:6233–6238
    [Google Scholar]
21. Levine A. J. 1990; The p53 protein and its interactions with the oncogene products of the small DNA tumor viruses. Virology 177:419–426
    [Google Scholar]
22. Medcalf E. A., Takahashi T., Chiba I., Minna J., Milner J. 1992; Temperature-sensitive mutants of p53 associated with human carcinoma of the lung. Oncogene 1:71–76
    [Google Scholar]
23. Mercer W. E., Shields M. T., Amin M., Sauve G. J., Appella E., Romano J. W., Ullrich S. J. 1990; Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proceedings of the National Academy of Sciences, U.S.A. 87:6166–6170
    [Google Scholar]
24. Raycroft L., Wu H., Lozano G. 1990; Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science 249:1049–1051
    [Google Scholar]
25. Rodrigues N. R., Rowan A., Smith M. E. F., Kerr I. B., Bodmer W. F., Gannon J. V., Lane D. P. 1990; p53 mutations in colorectal cancer. Proceedings of the National Academy of Sciences, U.S.A. 87:7555–7559
    [Google Scholar]
26. Sarnow P., Williams J., Levine A. J. 1982; Adenovirus Elb-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54kd cellular protein in transformed cells. Cell 28:387–394
    [Google Scholar]
27. Scheffner M., Werness B. A., Huibregtse J. M., Levine A. J., Howley P. M. 1990; The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129–1136
    [Google Scholar]
28. Shaulsky G., Goldfinger N., Rotter V. 1991; Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins. Cancer Research 51:5232–5237
    [Google Scholar]
29. Tarada K., Ono Y. 1989; Synchronous and sequential activation of latently infected Epstein-Barr virus genomes. Journal of Virology 63:445–449
    [Google Scholar]
30. Werness B. A., Levine A. J., Howley P. M. 1990; Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248:76–79
    [Google Scholar]
31. Wiman K. G., Magnusson K. P., Ramqvist T., Klein G. 1991; Mutant p53 detected in a majority of Burkitt lymphoma cell lines by monoclonal antibody PAb240. Oncogene 6:1633–1639
    [Google Scholar]
32. Yewdell J. W., Gannon J. V., Lane D. P. 1986; Monoclonal antibody analysis of p53 expression in normal and transformed cells. Journal of Virology 59:444–452
    [Google Scholar]
33. Yonish-Rouach E., Resnitzky D., Lotem J., Sachs L., Kimchi A., Oren M. 1991; Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature, London 352:345–347
    [Google Scholar]